Client News
OKYO Pharma Limited: Grant of options -PDMR dealing
London and Boston, M.A., 24 November, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces that the board of directors of the Company (the “Board” or “Directors”), acting on a recommendation of the Remuneration Committee has awarded Mr Raj Patil, the Company’s Chief Scientific Officer, a total of 5,000,000 options at an exercise price of 6.25 pence per share, in recognition of his work in achieving the recent IND filing for OK-101. The options vest immediately and have a life of five years.
This information set out below is provided in accordance with Article 19(3) of UK MAR.
https://www.londonstockexchange.com/news-article/OKYO/director-pdmr-shareholding/15728514
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.